IL-32 as a potential biomarker and therapeutic target in skin inflammation

Alexandra Wallimann; Mirjam Schenk

doi:10.3389/fimmu.2023.1264236

IL-32 as a potential biomarker and therapeutic target in skin inflammation

Front Immunol. 2023 Sep 1:14:1264236. doi: 10.3389/fimmu.2023.1264236. eCollection 2023.

Authors

Alexandra Wallimann¹, Mirjam Schenk^{1

2}

Affiliations

¹ Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
² Institute of Tissue Medicine and Pathology, Experimental Pathology, University of Bern, Bern, Switzerland.

Abstract

IL-32 is a recently described cytokine that performs a variety of functions under inflammatory conditions. Serum IL-32 has been shown to be elevated in several diseases, including type 2 diabetes, cancer, systemic lupus erythematosus, HIV infection, and atopic diseases including atopic dermatitis. There are nine different isoforms of IL-32, with IL-32γ being the most biologically active one. The following review summarizes the different roles of the various IL-32 isoforms in the context of skin inflammation, with a focus on atopic dermatitis.

Keywords: CTCL; IL-32; atopic dermatitis; infection; melanoma; skin inflammation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Dermatitis, Atopic* / drug therapy
Diabetes Mellitus, Type 2*
HIV Infections*
Humans
Inflammation

Substances

Biomarkers

Grants and funding

Supported by Christine Kühne -Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.